TMDX · TransMedics Group, Inc.
$70.74
-1.83% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$3B
Trailing P/E
18.3
Forward P/E
31.4
Dividend yield
0.0%
Beta
1.93
Avg volume
1M
Employees
1K
Daily Change %
-1.83%
5 Days Change
1.81%
10 Days Change
-8.94%
30 Days Change
-17.17%
60 Days Change
-23.01%
Month to Day Change
-8.37%
Year to Day Change
-40.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TMDX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-13
Latest call per bank · past 12 months
Barclays
Overweight$120
+69.6% vs priceUBS
Neutral$77.00
+8.8% vs priceJP Morgan
Neutral$149
+110.6% vs priceMorgan Stanley
Equal-Weight$135
+90.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Canaccord Genuity | Maintains | Buy | $95.00 → $94.00 |
| 2026-10-07 | Barclays | Initiates | Overweight | $0.00 → $120 |
| 2026-09-08 | TD Cowen | Reiterates | Buy | $120 |
| 2026-08-05 | UBS | Maintains | Neutral | $80.00 → $77.00 |
| 2026-08-05 | Piper Sandler | Reiterates | Overweight | $120 → $100 |
| 2026-08-03 | Needham | Maintains | Buy | $142 → $106 |
| 2026-07-28 | UBS | Initiates | Neutral | $0.00 → $80.00 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $100 → $90.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 15.7% below the 50-day MA ($83.90).
- bearish: Price vs 200-day MA: Trading 26.5% below the 200-day MA ($96.25).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.58) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($62.04) and high ($150.42).
TMDX Price Chart
Loading chart for TMDX…
Fundamentals
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
More in Medical Devices
ABT
Abbott Laboratories
$179B -16.2% YTD
MDT
Medtronic plc.
$122B 3.1% YTD
SYK
Stryker Corporation
$118B -11.9% YTD
BSX
Boston Scientific Corporation
$66B -51.7% YTD
EW
Edwards Lifesciences Corporatio
$51B 5.7% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.8% YTD
DXCM
DexCom, Inc.
$29B 18.0% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 3.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.